Our Take
Biotech IPO volume is recovering, but this is a market timing story, not a scientific one—four big closes tell you about Fed policy and venture appetite, not about which drugs will work.
Why it matters
Biotech funding cycles drive R&D runway and hiring in the sector. A rebound to 2021 pace after a dry 2023–2024 affects which programs get greenlit and how long companies can operate before proving efficacy.
Do this week
Finance and BD teams: check your company's cash runway against the new IPO window. If you are within 18 months of needing capital, accelerate clinical milestones to position for the next window in Q2–Q3 2026.
Kardigan joins a biotech IPO surge
Kardigan, a heart drug developer, closed a $400 million initial public offering this week. The raise marks the fourth biotech IPO of 2026 to exceed $400 million in proceeds, matching the highest annual tally since 2021, according to BioPharma Dive data.
The rebound follows a prolonged financing drought. From 2023 through mid-2025, biotech IPO activity dropped sharply as interest rates climbed and venture capital retreated from early-stage bets. The 2026 pace suggests investor confidence has returned to the sector, at least for candidates with enough clinical progress or market validation to command large public offerings.
Capital availability shapes pipeline speed
IPO windows open and close based on public market appetite, not scientific merit. When four large biotech companies can raise $400M+ in a single year, the second-order effect is runway. A company with $400M in the bank can fund Phase 3 trials, acquire smaller competitors, or extend cash burn for two to four years depending on burn rate.
The 2021 cohort that set the prior high-water mark included many entrants now in critical clinical stage. Some will fail. Some will be acquired. But the capital they raised bought time to test efficacy at scale. The 2026 cohort (of which Kardigan is one) is now buying the same optionality.
For investors and strategists, the pattern matters: biotech financing is cyclical and tied to macro conditions, not breakthrough science. A strong IPO year does not predict which drugs will be approved; it predicts which companies can afford to stay in the game long enough to find out.
What to do now
If you lead R&D, clinical, or business development at a biotech company with 12–36 months of cash remaining, treat this IPO window as a closing one. Public markets reward companies with clear clinical endpoints, partner agreements, or manufacturing scale. Prioritize de-risking trials and finalizing partnership terms now, because the next down cycle could close this window faster than it opened.
For downstream teams (manufacturing, regulatory, payer affairs), expect hiring acceleration over the next two quarters. Companies that just raised $400M typically spend 40–60% of that on clinical and regulatory headcount within 18 months. Lock contractors early if your firm supports biotech delivery.